Get started
Work

Histopathologic review of suspected disease progression in patients with recurrent glioblastoma (GBM) receiving nivolumab ± ipilimumab: CheckMate 143.

Year: 2017
Type: conference-abstract
DOI: 10.1200/jco.2017.35.15_suppl.2001
Authors: Solmaz Sahebjam, Shakti Ramkissoon, Joachim M. Baehring, Paul James Mulholland, Oliver M. Grauer, Timothy Francis Cloughesy, David A. Reardon, Michael Lim, Ricardo F. Zwirtes, Robert Raymond Latek, Lewis C. Strauss, Keith L. Ligon
Institutions: Moffitt Cancer Center, Foundation Medicine (United States), Yale University, University College Hospital, University College London, University of Münster, University Hospital Münster, University of California, Los Angeles, Harvard University, Dana-Farber Cancer Institute, Johns Hopkins University, Johns Hopkins Hospital, Bristol-Myers Squibb (United States)
Language: English
Subfield: Genetics
Field: Medicine
Open Access status: closed
OpenAlex ID: W2679639133
Cites:
Cited by: 2
Related to: 10